Benjamin Morin: Novel combinatorial immunotherapy regimen for gliomas

Benjamin Morin shared a post on LinkedIn about a paper by Kwang-Soo Kim et al. published in Neuro-Oncology.

“Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood–brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas”

Authors: Kwang-Soo Kim, Karl Habashy, Andrew Gould, Catalina Lee-Chang, Adam Sonabend et al.

“Great team work demonstrating that FC-enhanced anti-CTLA-4 together with anti-PD-1 and doxorubicin, when delivered with concomitant ultrasound-mediated blood-brain barrier opening, promotes robust anti-tumor effects in resistant murine gliomas!

These data are the basis for the ongoing collaborative clinical trial ((NCT05864534).”

Source: Benjamin Morin/LinkedIn

Benjamin Morin is the Senior Director at Agenus, where he focuses on preclinical portfolio strategy and development, overseeing target identification to IND. He previously served as a Postdoctoral Fellow at Harvard Medical School.